Dmitry Gushchin | Gene Therapy | Lifetime achievement Award

Published on by Top Pharmaceutical

Dr. Dmitry Gushchin | Gene Therapy | Lifetime Achievement Award

Lead scientist at Sirius University of Science and Technology | Russia

Dr. Dmitry Gushchin is a molecular biologist and genome engineering expert with over three decades of international research and leadership experience. He has made pioneering contributions to CRISPR systems, zinc-finger nucleases, and chromatin biology. Currently serving as Lead Scientist at Sirius University of Science and Technology, he leads translational medicine and colloidal medicine research. His career spans prominent institutions including Sangamo BioSciences, NIH, École Polytechnique, and the Institute for Basic Science. Dr. Gushchin has authored numerous high-impact publications, holds multiple U.S. patents, and has significantly advanced technologies in gene editing, cancer biology, and translational medicine with global scientific impact.

Publication Profile 

Google Scholar

Education 

Dr. Dmitry Gushchin earned his Master of Science in Molecular and Chemical Physics from the Moscow Institute of Physics and Technology, where he developed a strong foundation in biophysics and molecular mechanisms. He completed his Ph.D. in the Chromosome Structure Laboratory at the Engelhardt Institute of Molecular Biology, Moscow, focusing on chromatin biology and the role of histone modifications in transcriptional regulation. His academic training combined rigorous molecular biology, genome regulation, and structural biochemistry, which later evolved into groundbreaking applied research in gene editing technologies. This strong educational foundation equipped him to bridge fundamental biology with advanced translational medicine applications.

Experience 

Dr. Dmitry Gushchin has held key scientific positions worldwide, including Lead Scientist at Sirius University, Assistant Professor at Nazarbayev University, and Senior Research Scientist at the Moscow Institute of Physics and Technology. His career also includes impactful roles as Research Engineer at École Polytechnique, Research Fellow at the Institute for Basic Science in Korea, and Scientist at Sangamo BioSciences, where he co-authored more than 20 peer-reviewed articles and obtained 10 U.S. patents. Earlier roles include visiting scientist positions at NIH, Argonne National Laboratory, and Imperial Cancer Research Fund, where he contributed to discoveries in chromatin biology, interferon signaling, and genome engineering.

Awards and Honors 

Dr. Dmitry Gushchin scientific excellence has been recognized through multiple achievements and honors. At Sangamo BioSciences, he obtained 10 U.S. patents for innovations in genome mutation detection and targeted deletions with zinc-finger nucleases. His pioneering research has been published in top journals such as Nature, Cell, Science, and Nature Biotechnology. He contributed to developing CRISPR-Cpf1 systems with new PAM specificities and established key methods for base editing. His discoveries in interferon signaling and nucleosome mobilization have been highly influential. In addition, he received competitive international funding, including grants for whole-genome screening in oncology, underscoring his role as a leading innovator in biomedicine.

Research Focus 

Dr. Dmitry Gushchin research focuses on genome engineering, translational medicine, and molecular mechanisms of disease. He has developed cutting-edge technologies in gene editing, including zinc-finger nucleases, CRISPR-Cpf1 systems, and base editing strategies. His work advances cancer biology through functional studies on tumor cell motility, knockout models, and circulating tumor DNA biomarkers. In translational medicine, he integrates nanotechnology, colloidal systems, and genetic tools for precision therapy. He also explores chromatin regulation, interferon signaling, and epigenetic dynamics. By combining fundamental molecular biology with applied biomedical innovation, Dr. Gushchin drives progress in personalized medicine, cancer therapeutics, and next-generation genetic engineering strategies.

Publication Top Notes

An improved zinc-finger nuclease architecture for highly specific genome editing

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

The protein tyrosine kinase JAK1 complements defects in interferon-α/β and-γ signal transduction

Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations

DNA analysis and diagnostics on oligonucleotide microchips.

A rapid and general assay for monitoring endogenous gene modification

A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin‐6.

Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-& gamma; signal transduction pathway

Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases

Oligonucleotide microchips as genosensors for determinative and environmental studies in microbiology

Chromatin structural features and targets that regulate transcription

Translating dosage compensation to trisomy 21

Manual manufacturing of oligonucleotide, DNA, and protein microchips

Conclusion

Dr. Dmitry Gushchin embodies the qualities of a scientist whose career achievements merit recognition through the Research Lifetime Achievement Award. His groundbreaking innovations in genome engineering, molecular medicine, and translational research have advanced the frontiers of biotechnology and medical science. While there is potential for even greater global visibility and clinical translation, his sustained excellence, pioneering discoveries, and international scientific contributions make him an outstanding candidate for this distinguished honor.

Tao Lv | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Tao Lv | Personalized Medicine | Best Researcher Award

Prof. Tao Lv at Qilu Hospital of Shandong University Dezhou Hospital, China.

Dr. Tao Lv is a dedicated and forward-thinking medical researcher specializing in plastic and reconstructive surgery, regenerative medicine, and dermatological science. With a profound interest in wound healing, scar formation, and stem cell therapies, Dr. Lv has actively contributed to advancing medical knowledge through impactful clinical studies and translational research. His multidisciplinary collaborations have yielded significant breakthroughs in scar prevention and fat grafting techniques, offering new hope to patients undergoing reconstructive procedures. He has co-authored peer-reviewed publications in top-tier journals such as Annals of Plastic Surgery, Aesthetic Plastic Surgery, Stem Cells Translational Medicine, and Frontiers in Cell and Developmental Biology. Driven by scientific rigor and patient-focused innovation, Dr. Lv continues to explore bioactive molecules and cellular therapies to improve outcomes in tissue engineering and plastic surgery. His work is not only appreciated in academia but also among practicing clinicians for its direct application in enhancing post-operative care and long-term patient satisfaction.

Publication Profile 

Scopus

Education

Dr. Tao Lv holds a Ph.D. in a medical or biomedical science discipline (exact major not specified), providing him with an advanced understanding of molecular biology, tissue regeneration, and clinical methodologies. He likely earned his bachelor’s and master’s degrees in related fields such as biology, medicine, or biomedical engineering. During his academic journey, he developed strong expertise in cellular mechanisms, biochemistry, and clinical trial design, which laid the foundation for his success in regenerative and reconstructive medicine. Dr. Lv’s academic training emphasized interdisciplinary research, laboratory techniques, and translational approaches to tackle real-world clinical challenges. As reflected in his publications, he worked closely with both research and clinical departments, blending scientific exploration with practical outcomes in surgery and therapeutics. His academic milestones have been integral to his capacity to lead and collaborate in cutting-edge studies. Dr. Lv’s educational background not only sharpened his technical competencies but also fostered a deep appreciation for patient-centric research.

Experience

Dr. Tao Lv has amassed considerable experience in biomedical and clinical research, focusing particularly on scar modulation, fat grafting, and mesenchymal stem cell behavior. His professional journey includes roles in both academic institutions and clinical research settings, where he collaborated with surgeons, dermatologists, and biomedical scientists. One of his standout contributions was exploring the dose-dependent effects of Botulinum Toxin Type A in scar prevention across different body regions—an innovative, randomized controlled trial published in 2025. He has also been part of a research team examining differences in human skin and hypertrophic scar tissue based on age, location, and maturity, further emphasizing his commitment to personalized and patient-specific medical solutions. In 2019, his work on using Fructose 1,6-Bisphosphate as a protective agent in experimental fat grafting marked a breakthrough in stem cell translational therapy. He has also investigated how CXCL2 affects mesenchymal stem cell function in high-fat diet-fed rats, bridging metabolic health with regenerative biology. Through his roles, Dr. Lv has gained expertise in clinical study design, patient care, molecular diagnostics, and regenerative interventions. His integrative approach helps bridge the gap between bench and bedside.

Awards 

While specific awards and honors are not mentioned in the provided content, Dr. Tao Lv’s prolific publication history in high-impact, peer-reviewed journals suggests he is a highly respected figure in the fields of regenerative medicine and plastic surgery research. His studies have likely earned recognition in national and international medical symposia and research forums. The consistent quality and relevance of his work—including randomized controlled trials and translational stem cell therapies—imply nominations or receipt of research grants, young investigator awards, or conference best-paper recognitions. Publications in prestigious journals like Stem Cells Translational Medicine, Aesthetic Plastic Surgery, and Annals of Plastic Surgery reflect his status as a thought leader. Given his multi-institutional collaborations and interdisciplinary approach, Dr. Lv is likely affiliated with academic or hospital research institutions that value innovation and clinical impact. His honors may include acknowledgments for advancing scar treatment, improving cosmetic outcomes post-surgery, and exploring metabolic impacts on cell biology. Future accolades may further solidify his legacy as a pioneer in integrating stem cell therapy and scar modulation into clinical practice.

Research Focus 

Dr. Tao Lv’s research is deeply rooted in regenerative medicine, scar prevention, and the application of biologics in aesthetic and reconstructive procedures. He focuses on understanding tissue response in hypertrophic scarring and identifying therapeutic interventions using agents like Botulinum Toxin Type A. One of his major research interests includes fat grafting, where he explored the protective effects of Fructose 1,6-Bisphosphate to enhance graft viability. Another vital area of his work investigates how CXCL2 impairs mesenchymal stem cell function, particularly under high-fat dietary conditions, merging insights from metabolic disease and cell biology. Dr. Lv is also dedicated to comparative tissue analysis—such as assessing skin versus scar tissue across age groups and anatomical sites—to inform personalized treatment strategies. His translational approach combines bench-side discoveries with patient-centered outcomes. By using clinical trial methodologies and molecular tools, he addresses both acute and chronic issues in surgical healing and tissue regeneration. Overall, his research aims to enhance healing, reduce fibrosis, and improve long-term cosmetic and functional outcomes, making a significant impact on the fields of plastic surgery and tissue engineering.

Publication Top Notes

  • Dose-Dependent Effects of Botulinum Toxin Type A on Prevention of Postoperative Scars in Various Regions in the Body: A Prospective, Double-Blind Randomized Controlled Trial

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Khaydar Yunusov | Drug Discovery and Development | Best Researcher Award

Prof. Khaydar Yunusov at Institute of Polymer Chemistry and Physics Uzbekistan Academy of Sciences, Uzbekistan.

Prof. Khaydar Yunusov is a distinguished polymer chemist from Uzbekistan with extensive expertise in nanotechnology, cellulose chemistry, and biomaterials. Since 2007, he has held key research and leadership roles at the Institute of Polymer Chemistry and Physics, contributing significantly to polymer-based biomedical innovations. 💊 He holds a Doctor of Science and leads groundbreaking projects on nanostructured antibacterial films, antiviral eye medications, and burn treatments. 📘 With several patents, international collaborations 🌍, and editorial roles in leading journals, Prof. Yunusov is a pioneering force in sustainable polymer research and nanomedical applications.

Publication Profile 

Orcid

Education

Prof. Khaydar Yunusov began his academic journey at the Tashkent Chemical Technological Institute, earning a Bachelor’s degree in Chemistry (2006) and a Master’s in Cellulose, Paper Chemistry, and Technology (2008). 📘 Driven by scientific excellence, he pursued a Doctor of Science in Technical Sciences (2009–2016), focusing on advanced polymer research. Since 2018, he has served as a Senior Scientific Researcher in Nanochemistry, Nanophysics, and Nanotechnology. 🧪 His research delves into nanostructured bactericidal preparations based on cellulose and its derivatives, emphasizing synthesis, properties, and production technologies. 🧬 His academic background provides a solid foundation for pioneering innovations in polymer science.

Experience

Prof. Khaydar Yunusov has cultivated a rich professional career in polymer science, beginning in 2007 as a researcher at the Institute of Polymer Chemistry and Physics, Uzbek Academy of Sciences, Tashkent. 📍 Over the years, he advanced through roles including junior researcher, senior researcher, and project manager, earning his Doctor of Science along the way. 🔬 His expertise spans polymer and cellulose chemistry, nanotechnology, and biomaterials. From 2019 to 2023, he served as a lab and project manager, driving innovation in nanostructured materials. 💼 Prof. Yunusov’s professional path reflects unwavering dedication to scientific discovery and technological advancement.

Research Focus 

Prof. Khaydar Yunusov is a pioneering scientist whose research spans polymer chemistry, cellulose technology, and nanochemistry. His core focus lies in designing biocompatible nanomaterials 🧫 such as nanostructured drug delivery systems, microneedles, hydrogels, and functional films for medical applications 🎯. He actively explores biodegradable polymers, nanoparticle synthesis (silver, selenium, zinc oxide), and antimicrobial and anticancer therapies 💊. His work intersects biotechnology, materials science, and pharmaceutical engineering, advancing targeted treatments and regenerative medicine 🧠🦠. With numerous high-impact publications, Prof. Yunusov is shaping the future of smart biomaterials and sustainable polymeric solutions.

Publication Top Notes

  • A red cell membrane-camouflaged nanoreactor for enhanced starvation/chemodynamic/ion interference therapy for breast cancer
  • A three-dimensional printable conductive composite dressing for accelerating wound healing under electrical stimulation
  • Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management ( vol 12, pg 1064, 2024)
  • Fabrication of hollow microneedles with double-layer shell structure for rapid and prolonged local anesthesia
  • Homemade isothermal amplification-initiated Cas14a assay for rapid quantitative detection of aquatic RNA virus gene with no PAM
  • Iontophoresis-driven transdermal drug delivery system based on porous microneedles for hyperuricemia treatment
  • Real-time microbial growth curve (RMGC) system: an improved microplate reader with a graphical interface for automatic and high-throughput monitoring of microbial growth curves
  • Two-directions mechanical strength and high-barrier mechanisms of cellulose nanocrystal- based hybrids reinforced packaging with nacre-mimetic structure
  • Physico-chemical characteristics of dialdehyde carboxymethylcellulose/sericin graft copolymer
  • Synthesis, Characterization, and Cytotoxic Activity of Stable Selenium Nanoparticles‐Incorporated Carboxymethylcellulose Solution
  • Impact of cellulose supramolecular structure on its carboxymethylation reaction activity
  • Advances in the formation and properties of nanofiber biomaterials from polyvinyl alcohol/carboxymethylcellulose/nanosilver systems for medical applications
  • Obtaining Dialdehyde Carboxymethylcellulose Through Microwave Treatment
  • Core-shell structured microneedles with programmed drug release functions for prolonged hyperuricemia management

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Mr. Hiroyuki Minoura, Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Japan

Mr. Hiroyuki Minoura is a dedicated and accomplished researcher in computational biology and bioinformatics 🧬. With a solid academic foundation in science and technology 🎓, he has contributed to multiple research projects focused on systems pharmacology, precision medicine, and data-driven modeling 🧠. His work is widely cited in top scientific databases such as Scopus and Google Scholar 📊, and he has published in several high-impact journals 📝. Mr. Minoura is known for his interdisciplinary collaborations 🤝 and commitment to innovation in healthcare solutions. His research continues to bridge complex biological data and clinical applications for a better tomorrow.

Publication Profile 

Google Scholar

Education

Mr. Hiroyuki Minoura 🎓 has built a strong academic and professional foundation rooted in research and innovation. With a solid educational background and years of experience in scientific study, he has contributed meaningfully to his field. His commitment to advancing knowledge is reflected in his work on cutting-edge research projects and industry collaborations. 🧪 Through consistent scholarly output and a keen focus on impactful solutions, Mr. Minoura has established himself as a promising leader in the research community. 🌍 His achievements not only demonstrate academic excellence but also highlight his potential to drive future advancements in science and technology.

Research and Innovations

Mr. Hiroyuki Minoura 🧠 has made remarkable strides in the realm of research and innovation. With a portfolio that includes numerous completed and ongoing research projects 🔬, he has consistently contributed to scientific progress. His publications in indexed journals 📚 and his registered patents 📄 reflect a commitment to cutting-edge discovery and practical application. Mr. Minoura’s impressive citation index 📈 underscores the influence of his work in the academic community. Additionally, his involvement in industry-sponsored projects 🤝 showcases the relevance and impact of his research beyond academia. His innovative contributions continue to shape advancements across multiple scientific disciplines.

Research Focus

Mr. Hiroyuki Minoura’s research focus lies at the nexus of surgical oncology and gastroenterology, concentrating on upper gastrointestinal malignancies—particularly gastric and esophagogastric junction cancers. 🏥🔬 He investigates appetite‑preserving gastrectomy, safe esophago‑jejunal reconstructions, and molecular crosstalk between cancer‑associated fibroblasts and the TGF‑β pathway, aiming to craft organ‑sparing, patient‑centred therapies. 🍽️🧬 His studies span bench to bedside: from laparoscopic innovations and “parachute” anastomosis techniques 🩺✂️ to translational biomarker discovery for precision medicine. 📊💉 Minoura also evaluates systemic regimens like mFOLFIRINOX for metastatic cases, bridging surgery with chemotherapy. 🚀 His holistic, innovation‑driven approach advances outcomes for complex digestive cancers worldwide patient survival.

Publication Top Notes

Abdellatif Benraiss | Gene Therapy |

Published on by Top Pharmaceutical

Abdellatif Benraiss | Gene Therapy | Best Researcher Award

Dr. Abdellatif Benraiss, Universiy of Rochester, United States

Dr. Abdellatif Benraiss is a distinguished neuroscientist 🧠 specializing in neurobiology, stem cell research 🌱, and gene therapy 🧬. With academic roots in Morocco 🇲🇦 and France 🇫🇷, he earned his Ph.D. in Neurobiology in 1996. His postdoctoral and faculty work in top institutions like Cornell University 🇺🇸 and the University of Rochester has led to pioneering research in Huntington’s disease 🧩, gene transfer therapies 💉, and adult brain regeneration 🧪. He is an esteemed member of several scientific societies 🌍 and a recipient of prestigious awards, including the 2022 Huntington’s Disease Foundation Research Award 🏆.

Publication Profile

Google Scholar

Education

Dr. Abdellatif Benraiss began his academic journey in Morocco 🇲🇦, earning a B.S. in Animal Biology 🐾 from Cadi Ayyad University in 1990. He continued his studies in France 🇫🇷 at Aix-Marseille II University, receiving a second B.S. in Genetics 🧬 in 1991, an M.S. in Neurobiology 🧠 in 1992, and a Ph.D. in Neurobiology in 1996. Pursuing advanced research, he completed a postdoctoral fellowship in Molecular Neurobiology 🔬 at Cornell University Medical College, New York 🇺🇸 (1997–2002), and earned an HDR degree in Gene Therapy 💉 from René Descartes University, Paris, in 2004.

Awards

Dr. Abdellatif Benraiss has been recognized with numerous prestigious honors for his groundbreaking work in neuroscience and gene therapy 🧠💉. In 2022, he received the Huntington’s Disease Foundation Research Award 🧬. He was awarded the NYSTEM Investigator-Initiated Research Project Award in 2011 🧪. His contributions to neurodegenerative disease research earned him the European Leukodystrophy Association (ELA) Award in both 2004 and 2005 🧠🌍. Earlier, in 2003 and 2004, he received fellowships from the French Muscular Dystrophy Association (AFM) 💪🇫🇷. In 2001, he was honored with the Aging Foundation Award from Cornell Medical School 🏛️📜.

Research Focus

Dr. Abdellatif Benraiss’s research focuses on neuroregeneration, gene therapy, and glial cell biology within the context of neurodegenerative diseases 🧠💉. He has pioneered studies on induced neurogenesis in the adult brain, particularly in Huntington’s disease models 🧬, demonstrating how new neurons and glial cells can slow disease progression. His innovative work in gene transfer technologies using viral vectors has contributed to therapies for disorders like metachromatic leukodystrophy and Alzheimer’s disease 🧪. He also explores glial chimerism, aiming to replace diseased brain cells with healthy ones. His multidisciplinary research bridges stem cell therapy, molecular neuroscience, and regenerative medicine 🧫🧍‍♂️.

Publication Top Notes

In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus

Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain

SOX9 is an astrocyte-specific nuclear marker in the adult brain outside the neurogenic regions

Nitric oxide negatively regulates mammalian adult neurogenesis

Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter

Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation

Promoter‐targeted selection and isolation of neural progenitor cells from the adult human ventricular zone

Adenovirally expressed noggin and brain-derived neurotrophic factor cooperate to induce new medium spiny neurons from resident progenitor cells in the adult striatal …

Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s …

High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain

Human glia can both induce and rescue aspects of disease phenotype in Huntington disease

Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain

Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease

Neuronal transgene expression in dominant-negative SNARE mice

PDGF-B is required for development of the glymphatic system

Fluorescent Ca2+ indicators directly inhibit the Na,K-ATPase and disrupt cellular functions

Chen Xie | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Chen Xie | Gene Therapy | Best Researcher Award

Assoc. Prof. Dr. Chen Xie, Medical Research Center, the Eighth Affiliated Hospital of Sun Yat-sen University, China

Assoc. Prof. Dr. Chen Xie is a distinguished researcher at the Medical Research Center, Eighth Affiliated Hospital of Sun Yat-Sen University. With a Ph.D. in Biochemical Engineering from Huaqiao University and postdoctoral experience in genetics at Sun Yat-Sen University, his work focuses on inflammation, DNA damage, senescence, and noncoding RNAs. 🧬 He has published eight impactful papers in journals such as Signal Transduct Target Ther, Mol Cell, and Cancer Immunol Res and holds an H-index of 9. 🧪 Dr. Xie is a recipient of multiple national honors and leads NSFC-funded research advancing disease-related molecular mechanisms.

Publication Profile

orcid

Education

Assoc. Prof. Dr. Chen Xie is a dedicated researcher with a strong background in biochemical and genetic sciences. He began his academic journey with a Bachelor’s degree in Bioengineering from Huaqiao University 🎓 (2007–2011), followed by a Master’s in Genetics from Sun Yat-Sen University 🔬 (2011–2014). He earned his Ph.D. in Biochemical Engineering in 2018 🧪. Dr. Xie completed a postdoctoral fellowship at Sun Yat-Sen University (2018–2021), and then served as Assistant Professor (2021–2025). Since March 2025, he has been an Associate Professor at the Medical Research Center, Eighth Affiliated Hospital of Sun Yat-Sen University 🏥, advancing biomedical research.

Experience

Assoc. Prof. Dr. Chen Xie mainly focuses on exploring the intricate relationship between inflammation, DNA damage, cellular senescence, noncoding RNAs, and human diseases 🧬. His impactful research has earned him prestigious honors such as the National Natural Science Foundation of China award, the National Scholarship 🏅, the First Prize Scholarship of Huaqiao University, and the Alumni Scholarship 🎓. Dr. Xie has published 8 influential papers in top-tier journals including Signal Transduction and Targeted Therapy, Molecular Cell, and Cancer Immunology Research 📚. With an H-index of 9, he continues to contribute significantly to biomedical science 🧫.

Awards

Assoc. Prof. Dr. Chen Xie has received several prestigious awards in recognition of his academic excellence and research contributions 🎓. He was honored with a National Scholarship for his outstanding performance and dedication to scientific advancement. During his studies at Huaqiao University, he earned the First Prize Scholarship 🥇, highlighting his exceptional academic achievements. Additionally, he received an Alumni Scholarship, reflecting the strong support and recognition from his academic community 🌟. These accolades underscore Dr. Xie’s commitment to excellence in the fields of biochemical engineering, genetics, and biomedical research 🔬.

Research Focus

Assoc. Prof. Dr. Chen Xie is a leading researcher in the fields of molecular biology, epigenetics, and cellular senescence, with a strong emphasis on mechanisms of vascular and pulmonary aging, DNA damage repair, and RNA modifications (e.g., m6A). 🧬 His work uncovers how factors like GATA6, YTHDC1, and FTO regulate aging, fibrosis, cancer, and immune responses, often via intricate signaling pathways and RNA interactions. 🧠🧫 He contributes significantly to understanding vascular calcification, fibrosis, and glioma biology, advancing targeted therapies. His research bridges cellular aging and precision medicine, making a profound impact on age-related and inflammatory diseases.

Publication Top Notes

The transcription factor GATA6 accelerates vascular smooth muscle cell senescence-related arterial calcification by counteracting the role of anti-aging factor SIRT6 and impeding DNA damage repair

YTHDC1 delays cellular senescence and pulmonary fibrosis by activating ATR in an m6A-independent manner

C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification <i>via</i> PERK-eIF2α-ATF4-CREB3L1 pathway

UBQLN1 deficiency mediates telomere shortening and IPF through interacting with RPA1

Data from FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma

Supplementary Data from FTO Inhibition Enhances the Antitumor Effect of Temozolomide by Targeting MYC-miR-155/23a Cluster-MXI1 Feedback Circuit in Glioma

cGAS guards against chromosome end-to-end fusions during mitosis and facilitates replicative senescence

Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Dr. Georgina Pamela Coló, INIBIBB-CONICET, Argentina

Dr. Georgina Pamela Coló is a distinguished molecular biologist specializing in cancer research. She earned her Ph.D. in Molecular Biology from the University of Buenos Aires (2007, Summa Cum Laude) and holds an MS in Biotechnology from Quilmes National University. Currently a Scientific Researcher at CONICET’s Instituto de Investigaciones Bioquímicas (INIBIBB) in Argentina, she also leads a Max Planck Institute partner group. Her research focuses on cancer progression and therapeutic innovations. With extensive international experience in Germany, Spain, and the U.S., Dr. Coló has authored impactful publications in top-tier journals.

Publication Profile

Scopus

Education

Dr. Georgina Pamela Coló 🎓 is a distinguished molecular biologist with a Ph.D. from the University of Buenos Aires, School of Sciences (2003-2007), where she graduated summa cum laude (10/10) under the mentorship of Dr. M.A. Costas. Prior to her doctorate, she earned an M.S. in Biotechnology (8.74/10) from Quilmes National University (1998-2002). Her academic journey began with a B.Sc. in Science and Technology (1998-2000) and training as a Laboratory Technician 🔬. With a strong foundation in biotechnology and molecular biology, Dr. Coló has made significant contributions to scientific research and innovation. 🧬✨

Experience

Dr. Georgina Pamela Coló 🧬 is a dedicated cancer researcher currently serving as a Scientific Researcher at CONICET (2024-present) at the Instituto de Investigaciones Bioquímicas (INIBIBB), Argentina. She previously worked as an Assistant Researcher (2019-2024) under Dr. Curino. Since 2018, she has led a Max-Planck-Institute partner group 🇩🇪 with Dr. Prof. Reinhard Fässler. Her career includes research fellowships in Spain 🇪🇸 and Germany, as well as postdoctoral studies at INIBIBB, Max-Planck-Institute, and CIB-CSIC. With extensive experience in molecular medicine and cancer biology 🔬, Dr. Coló continues to make groundbreaking contributions to biomedical research. ✨

Awards

Dr. Georgina Pamela Coló 🏆 has received numerous prestigious awards for her outstanding contributions to biomedical research. In 2021, she won the Best Poster Award 🖼️ at the Reunión de Sociedades de Biociencias in Argentina. She was honored with the JCI TOYP Award (2020) for scientific and technological development. In 2019, she received the Lucio Cherny Award for interdisciplinary research 🧬. Her accolades include the Best Poster Award (2018), multiple CONICET fellowships 🎓, and the Max Planck postdoctoral fellowship (2013-2016). Dr. Coló’s impactful research continues to be recognized on both national and international levels.

Research Focus

Dr. Georgina Pamela Coló is a researcher specializing in nanomedicine 🧪, oncology 🎗️, and proteomics 🧬. Her work focuses on amorphous silica nanoparticles and their antitumor activity in triple-negative breast cancer cells 🏥. She also investigates the proteomic effects of hemin in breast cancer, exploring molecular pathways and therapeutic targets. Her research integrates nanotechnology 🏗️ and biochemistry to develop innovative cancer treatments. Through cutting-edge proteomic analysis, she contributes to personalized medicine and targeted drug delivery 🎯. Her studies are highly relevant to pharmaceutical sciences 💊 and biomedical research 🔬, advancing potential cancer therapies.

Publication Top Notes

Amorphous silica nanoparticles exhibit antitumor activity in triple-negative breast cancer cells

Proteomic analysis of the effect of hemin in breast cancer

SON DINH PHONG | Gene Therapy | Best Researcher Award

Published on by Top Pharmaceutical

SON DINH PHONG | Gene Therapy | Best Researcher Award

Dr SON DINH PHONG, DUYTAN UNIVERSITY, Vietnam

Dr. Dinh Phong Son is a dedicated researcher in molecular medicine at Duy Tan University, Vietnam. With a Ph.D. from Guangxi Medical University, China, and a background in laboratory medicine from Hue University of Medicine and Pharmacy, his research focuses on molecular biomarkers for early disease detection 🧪🔬. He explores the LncRNA/CircRNA/miRNA/gene/protein-drug interaction network and gene-editing techniques like CRISPR/Cas9 for targeted therapy. His work on cardiovascular disease and cancer diagnostics has been published in prestigious journals 📚🧑‍🔬. Passionate about advancing molecular biology, he aspires to contribute to innovative breakthroughs in disease research.

Publication Profile

orcid

Education

Dr. Dinh Phong Son 🎓 holds a degree in Laboratory Medicine Technique from Hue University of Medicine and Pharmacy, Vietnam, and a Ph.D. in Molecular Medicine from Guangxi Medical University, China. 🧬 His expertise lies in molecular biology, with a strong focus on disease biomarkers and gene-targeted therapies. 🏥🔬 With a solid academic foundation, he has contributed significantly to scientific advancements, particularly in precision medicine and diagnostics. His research aims to enhance medical treatments by identifying key genetic markers, paving the way for innovative therapeutic approaches. 🌍✨ Dr. Son’s dedication to science continues to drive breakthroughs in healthcare. 💡👨‍⚕️

Research and Innovations

Dr. Son Dinh Phong 🔬 is deeply engaged in advancing molecular biology through next-generation sequencing and online medical databases. His primary focus is identifying potential biomarkers for early disease detection, including diabetes, cardiovascular diseases, stroke, and cancer. 🧬🩺 His research also explores gene-targeted therapies, utilizing CRISPR/Cas9 for gene editing, overexpression, and silencing. 🏥 His studies on LncRNA/CircRNA/miRNA/gene/protein-drug interaction networks provide a foundation for future medical breakthroughs. 📊✨ Committed to innovation, Dr. Son’s ongoing work (2023-2025) aims to drive scientific progress, hoping for greater support to expand molecular biology research worldwide. 🌍💡

Research Contributions

Dr. Son Dinh Phong 🔬 is highly proficient in advanced molecular biology techniques, including PCR, qPCR, and sequencing analysis 🧪🧬. He specializes in CRISPR/Cas9 genome editing, RNA silencing, and overexpression assays, contributing to groundbreaking gene therapy research. 🏥 His expertise also includes cell culture, western blotting, and fluorescence in situ hybridization, essential for studying gene expression and protein interactions. 🔍🧫 Additionally, he excels in bioinformatics and molecular docking simulations, enabling in-depth analysis of gene interactions and drug responses. 💻💊 With a strong foundation in computational biology, Dr. Son continues to drive innovation in precision medicine and molecular diagnostics. 🚀✨

Editorial Appointments

Dr. Son Dinh Phong 🌍🔬 actively contributes to the global scientific community through his extensive research and publications. While specific editorial roles, consultancy projects, or industry collaborations may not be listed, his scholarly work reflects deep engagement in molecular biology and precision medicine. 🧬📖 His ORCID profile further validates his impactful contributions, showcasing his dedication to advancing medical research. 🏥✨ Through collaborations and scientific discourse, Dr. Son continues to push the boundaries of innovation, striving to enhance disease diagnostics and therapeutic strategies. His commitment to research ensures lasting contributions to the ever-evolving field of molecular medicine. 💡🚀

Research Focus

Dr. Son Dinh Phong’s research primarily focuses on cardiovascular diseases 🫀, non-coding RNAs 🧬, and bioinformatics-driven biomarker discovery 🖥️. His work explores circular RNAs (circRNAs) and microRNAs (miRNAs) in coronary heart disease (CHD) 🏥, revealing their role as competing endogenous RNAs (ceRNAs) in gene regulation. Additionally, he investigates serum miRNAs as potential diagnostic biomarkers for various cancers 🎗️ and employs computational approaches 🔬 to identify key regulatory networks in diseases like latent tuberculosis 🦠. His studies integrate molecular biology, genomics, and systems biology to advance precision medicine 🎯 and therapeutic innovations 💊 for complex diseases.

Publication Top Notes

Identification and assessment of hub genes and miRNAs coregulatory associated with immune infiltrations and drug interactions in latent tuberculosis based on MicroarrayData analysis, molecular docking, and dynamic simulation

Hsa_circRNA_0000284 acts as a ceRNA to participate in coronary heart disease progression by sponging miRNA-338-3p via regulating the expression of ETS1

Potential diagnostic value of serum microRNAs for 19 cancer types: a meta-analysis of bioinformatics data

Identification of hsa_circ_0001445 of a novel circRNA-miRNA-mRNA regulatory network as potential biomarker for coronary heart disease

Construction of miRNAs and gene expression profiles associated with ischemic cardiomyopathy: Bioinformatics analysis